Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges

Health Affairs

Volumn 28, Issue 5, 2009, Pages

  Crystal, Stephen ^a   Olfson, Mark ^b   Huang, Cecilia ^c   Pincus, Harold ^b   Gerhard, Tobias ^d  

^a The State University of New Jersey   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c CHSR PCDMO ^*

^d RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; NURSING HOME PATIENT; OFF LABEL DRUG USE; PATIENT SAFETY; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; RISK BENEFIT ANALYSIS;

ADOLESCENT; AGED; ANTIPSYCHOTIC AGENTS; CHILD; DRUG UTILIZATION; HEALTH POLICY; HUMANS; INSURANCE, HEALTH; NURSING HOMES; OFF-LABEL USE; PRIVATE SECTOR; UNITED STATES;

EID: 70349202409     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.5.w770     Document Type: Article

References (42)

1. See P. Shekelle et al., Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics, Comparative Effectiveness Review no. 6, January 2007, http://www.effectivehealthcare.ahrq.gov/repFiles/Atypical-Antipsychotics-Final- Report.pdf (accessed 1 July 2009).
2. IMS Health, "2007 Top Therapeutic Classes by U.S. Sales," 2008, http://imshealth.com/imshealth/Global/Content/Document/Top- Line%20Industry%20Data/ 2006%20Top%2010%20Therapeutic%20Classes%20by%20US%20Sales.pdf (accessed 1 July 2009).
3. D. Esposito et al., "Trends in Medicaid Prescription Drug Use and Costs, 1999 to 2002: Evidence from Medicaid Analytic Extract Data," Presented at the Academy Health Annual Research Meeting, Washington, D.C., June 2007;
4. and Centers for Medicare and Medicaid Services, Chartbook: Medicaid Pharmaceutical Benefit Use and Reimbursement in 2003, http://www.cms.hhs.gov/ MedicaidDataSourcesGenInfo/downloads/Pharmacy-RX-Chartbook-2003.pdf (accessed 1 July 2009).
5. For a description of our data sources, study population, and study methods, see the Methods Appendix, online at http:content.healthaffairs.org/cgi/ content/full/hlthaff.28.5.w770/DC2.
6. M. Olfson et al., "National Trends in the Outpatient Treatment of Children and Adolescents with Antipsychotic Drugs," Archives of General Psychiatry 63, no.6 (2006): 679-685.
7. R. Constantine and R. Tandon, "Changing Trends in Pediatric Antipsychotic Use in Florida's Medicaid Program," Psychiatric Services 59, no.10 (2008): 1162-1168.
8. W.O. Cooper et al., "New Users of Antipsychotic Medications among Children Enrolled in TennCare," Archives of Pediatrics and Adolescent Medicine 158, no.8 (2004): 753-759.
9. L. Sikich et al., "Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-Affective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study," American Journal of Psychiatry 165, no.11 (2008): 1420-1431.
10. C.U. Correll, "Monitoring and Management of Antipsychotic-Related Metabolic and Endocrine Adverse Events in Pediatric Patients," International Review of Psychiatry 20, no.2 (2008): 195-201.
11. V. Shrewsbury and J. Wardle, "Socioeconomic Status and Adiposity in Childhood: A Systematic Review of Cross-Sectional Studies, 1990-2005," Obesity 16, no.2 (2008): 275-284.
12. Henry J. Kaiser Family Foundation, Health Insurance Coverage of America's Children, January 2007, http://www.allhealth.org/BriefingMaterials/ HealthInsuranceCoverageofAmericasChildren-549.pdf (accessed 1 July 2009).
13. S. Glied et al., "Children's Access to Mental Health Care: Does Insurance Matter?" Health Affairs 16, no.1 (1997): 167-174;
14. and A. Martin et al., "Datapoints: Use of Multiple Psychotropic Drugs by Medicaid- Insured and Privately Insured Children," Psychiatric Services 53, no.12 (2002): 1508.
15. N.C. Patel et al., "Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents," Journal of the American Academy of Child and Adolescent Psychiatry 44, no.6 (2005): 548-556. (Pubitemid 40720954)
16. D.V. Jeste et al., "ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia," Neuropsychopharmacology 33, no.5 (2008): 957-970.
17. R.I. Shorr, R.L. Fought, and W.A. Ray, "Changes in Antipsychotic Drug Use in Nursing Homes during Implementation of the OBRA-87 Regulations," Journal of the American Medical Association 271, no.5 (1994): 358-362.
18. C. Salzman et al., "Elderly Patients with Dementia-Related Symptoms of Severe Agitation and Aggression: Consensus Statement on Treatment Options, Clinical Trials Methodology, and Policy," Journal of Clinical Psychiatry 69, no.6 (2008): 889-898.
19. L.S. Schneider, K.S. Dagerman, and P. Insel, "Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia:Meta-Analysis of Randomized Placebo-Controlled Trials," Journal of the American Medical Association 294, no.15 (2005): 1934-1943.
20. L.S. Schneider, K.S. Dagerman, and P. Insel, "Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia:Meta-Analysis of Randomized Placebo-Controlled Trials," Journal of the American Medical Association 2005): 15 (294, no.1934-1943.Ibid.
21. L.S. Schneider et al., "Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease," New England Journal of Medicine 355, no.15 (2006): 1525-1538. (Pubitemid 44547805)
22. Salzman et al., "Elderly Patients with Dementia-Related Symptoms";
23. and Jeste et al., "ACNP White Paper."
24. M.B. First, H.A. Pincus, and M. Schoenbaum, "Issues for DSM-V: Adding Problem Codes to Facilitate Assessment of Quality of Care," American Journal of Psychiatry 166, no.1 (2009): 11-13.
25. Sikich et al., "Double-Blind Comparison";
26. and Correll, "Monitoring and Management."
27. J.M. Zito et al., "A Three-Country Comparison of Psychotropic Medication Prevalence in Youth," Child and Adolescent Psychiatry and Mental Health 2, no.1 (2008): 26.
28. T.P. Gilmer et al., "Antipsychotic Polypharmacy Trends among Medicaid Beneficiaries with Schizophrenia in San Diego County, 1999-2004," Psychiatric Services 58, no.7 (2007): 1007-1010;
29. J.M. Zito et al., "Psychotropic Medication Patterns among Youth in Foster Care," Pediatrics 121, no.1 (2008): e157-e163;
30. and S.J. Kogut, F. Yam, and R. Dufresne, "Prescribing of Antipsychotic Medication in a Medicaid Population: Use of Polytherapy and Off-Label Dosages," Journal of Managed Care Pharmacy 11, no.1 (2005): 17-24.
31. M.R. Law, D. Ross-Degnan, and S.B. Soumerai, "Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements," Psychiatric Services 59, no.5 (2008): 540-546.
32. A.P. Farmer et al., "Printed Education Materials: Effects on Professional Practice and Health Care Outcomes," Cochrane Database of Systematic Reviews 16, no.3 (2008): CD004398.
33. S.B. Soumerai and J. Avorn, "Principles of Educational Outreach ('Academic Detailing') to Improve Clinical Decision Making," Journal of the American Medical Association 263, no.4 (1990): 549-556.
34. G. Jamtvedt et al., "Audit and Feedback: Effects on Professional Practice and Health Care Outcomes," Cochrane Database of Systematic Reviews 19, no.2 (2006): CD000259.
35. J.E Wilk et al., "Medicare Part D Prescription Drug Benefits and Administrative Burden in the Care of Dually Eligible Psychiatric Patients," Psychiatric Services 59, no.1 (2008): 34-39.
36. Law et al., "Effect of Prior Authorization";
37. and J.C. West et al., "Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients during the First Four Months of the Medicare Prescription Drug Benefit," American Journal of Psychiatry 164, no.5 (2007): 789-796.
38. J.M. Polinski, P.S. Wang, and M.A. Fischer, "Medicaid's Prior Authorization Program and Access to Atypical Antipsychotic Medications," Health Affairs 26, no.3 (2007): 750-760.
39. J.N. Thompson et al., "Second Opinions Improve ADHD Prescribing in a Medicaid-Insured Community Population," Journal of the American Academy of Child and Adolescent Psychiatry 48, no.7 (2009): 740-748.
40. G. Harris, "Use of Antipsychotics in Children Is Criticized," New York Times, 18 November 2008.
41. National Committee for Quality Assurance, "The State of Health Care Quality 2006" (Washington: NCQA, 2006);
42. and R.W. Bremer et al., "Pay for Performance in Behavioral Health," Psychiatric Services 59, no.12 (2008): 1419-1429.